| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | -100.0% |
| R&D Expense | $34.4M | +6.9% |
| SG&A Expense | $26.4M | -29.1% |
| Operating Income | -$61.0M | +34.2% |
| Net Income | -$52.8M | +25.7% |
| EPS (Basic) | -$12.03 | -651.9% |
| EPS (Diluted) | -$12.03 | -651.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $48.3M | +34.4% |
| Current Assets | $59.0M | -17.2% |
| Total Assets | $97.8M | -18.1% |
| Current Liabilities | $13.1M | +3.7% |
| Total Liabilities | $47.1M | -10.4% |
| Stockholders' Equity | $25.6M | -61.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$41.4M | +21.0% |
| Capital Expenditures | $26K | -99.8% |
| Investing Cash Flow | $34K | -99.9% |
| Financing Cash Flow | $53.7M | +6797.3% |
| Free Cash Flow | -$41.4M | +35.7% |